MiNK Therapeutics (NASDAQ:INKT – Get Free Report) and Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.
Analyst Ratings
This is a breakdown of current recommendations and price targets for MiNK Therapeutics and Kymera Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MiNK Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| Kymera Therapeutics | 0 | 4 | 8 | 1 | 2.77 |
MiNK Therapeutics currently has a consensus price target of $9.00, indicating a potential upside of 1,060.54%. Kymera Therapeutics has a consensus price target of $48.67, indicating a potential upside of 5.61%. Given MiNK Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe MiNK Therapeutics is more favorable than Kymera Therapeutics.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MiNK Therapeutics | N/A | N/A | -$22.46 million | ($0.60) | -1.29 |
| Kymera Therapeutics | $88.55 million | 31.93 | -$146.96 million | ($2.51) | -18.36 |
MiNK Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
2.9% of MiNK Therapeutics shares are held by institutional investors. 17.8% of MiNK Therapeutics shares are held by company insiders. Comparatively, 15.8% of Kymera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
MiNK Therapeutics has a beta of 0.06, suggesting that its stock price is 94% less volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.22, suggesting that its stock price is 122% more volatile than the S&P 500.
Profitability
This table compares MiNK Therapeutics and Kymera Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MiNK Therapeutics | N/A | N/A | -233.85% |
| Kymera Therapeutics | -178.27% | -28.88% | -22.37% |
Summary
MiNK Therapeutics beats Kymera Therapeutics on 9 of the 14 factors compared between the two stocks.
About MiNK Therapeutics
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
About Kymera Therapeutics
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
